Slide 1: COVALENT-111: Phase II First Data Readout of Initial HV and T2DM Cohorts
Exhibit 99.2 COVALENT-111: Phase II First Data Readout of Initial Healthy Volunteer (HV) and Type 2 Diabetes Mellitus (T2DM) Cohorts March 28, 2023
Slide 2: Legal Disclaimer & Forward-Looking Statements
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 Legal Disclaimer & Forward-Looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future busine
Slide 3: Agenda
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 Agenda Introduction Ramses Erdtmann Chief Operating Officer & Co-Founder of Biomea Diabetes Background & Overview Dr. Juan Frias Medical Director & Principal Investigator of Velocity Clinical Research, Scientific Adv
Slide 4: Type 2 Diabetes Progression is Driven by Loss of Beta Cell Mass
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 Type 2 Diabetes Progression is Driven by Loss of Beta Cell Mass Type 1 and Type 2 Diabetes both result in Beta Cell Loss and Reduction in Beta Cell Mass Current Diabetes Therapies are typically not observed to addres
Slide 5: Menin – Downregulated by Prolactin during Pregnancy Allowing for Beta Cell Expansion
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 Menin – Downregulated by Prolactin during Pregnancy Allowing for beta cell expansion and prevention of gestational diabetes • Stanford researchers have observed that during pregnancy, maternal pancreatic islets grow
Slide 6: Summary of Results
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 Summary of Results Cohort 2 Cohort 3 BMF-219 Placebo BMF-219 Placebo Number of Subjects 10 2 10 2 400 mg Exposure: C (ng/mL)/ AUC max 34.8 / 84.3 - 94.2 / 224 - (hr*ng/mL) 200 mg Median (Mean) HbA1c % at 7.9 (8.0) 8.
Slide 7: COVALENT-111: Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Study Design
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 COVALENT-111: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-219, an Oral Covalen
Slide 8: Dose Escalation Phase (Oral, Daily Dosing X 28 days)
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 Dose Escalation Phase (Oral, Daily Dosing X 28 days) Day 1 Week 4 Week 26 Dosing Scheme Dosing Period Follow-up Period 400 mg § Dose Escalation Phase (Total N) = 60 Type 2 Diabetes Coming soon - Each dose cohort [N=1
Slide 9: COVALENT-111 Baseline Patient Characteristics
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 COVALENT-111 Baseline Patient Characteristics Cohort 2 Cohort 3 BMF-219 Placebo BMF-219 Placebo Number of Subjects 10 2 10 2 Age (min, max) 35, 60 40, 53 38, 63 35, 61 Sex (M, F) 7, 3 2, 0 6, 4 2, 0 Time since T2DM 4
Slide 10: Observed HbA1c Lowering of BMF-219
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 Observed HbA1c Lowering of BMF-219 Cohort 2 Response Rate 70% of patients responded to BMF-219 HbA1c (all pts) Median Baseline: 7.9% Median ∆: - 0.3% (at week 4) Cohort 3 Response Rate 89% of patients responded to BM
Slide 11: COVALENT-111 HbA1c Summary Results at Week 4
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 COVALENT-111 HbA1c Summary Results at Week 4 Cohort 2 Cohort 3 BMF-219 Placebo BMF-219 Placebo Number of Subjects 10 2 10 2 HbA1c (%) at Baseline 7.1 – 9.1 7.0 – 9.8 Median HbA1c (Mean) (%) 7.9 (8.0) 8.4 (8.4) 7.8 (8
Slide 12: Case Report Cohort Patient Results (Patient A): Glycemic Parameters
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 Case Report Cohort 3 Patient Results (Patient A): Glycemic Parameters Continuous Glucose Monitoring Continuous Glucose Monitoring Baseline Week 4 + • Average glucose 169 mg/dL • Average glucose 205 mg/dL • 72% time i
Slide 13: Case Report Cohort Patient Results (Patient B): Glycemic Parameters
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 Case Report Cohort 3 Patient Results (Patient B): Glycemic Parameters Continuous Glucose Monitoring Continuous Glucose Monitoring Baseline Week 4 + • Average glucose 174 mg/dL • Average glucose 234 mg/dL • 60% time i
Slide 14: All Treatment Emergent Adverse Events (Healthy Volunteers)
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 COVALENT-111 Cohort 1 All Treatment Emergent Adverse Events (TEAEs) (Healthy Volunteers, n=16; 100 mg once daily for 14 days) Preferred Term for BMF-219 Placebo Total TEAE (N=12) (N=4) (N=16) Subjects with ≥1 TEAE 2
Slide 15: All TEAEs (Type 2 Diabetes)
COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 COVALENT-111 Cohort 2 & 3 All TEAEs (Type 2 Diabetes n=24; 100 mg once daily dosing X 4 weeks) BMF-219 Placebo Total Preferred Term for TEAE (N=20) (N=4) (N=24) Subjects with ≥1 TEAE 7 (35%) 2 (50%) 9 (38%) Abdominal
Slide 16: Summary of Data
COVALENT 111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 Summary of Data Safety • BMF-219 demonstrated a well-tolerated safety profile • No dose discontinuations • All 20 subjects completed 4 weeks of treatment and continue in 5-month follow-up period • No severe or seriou
Slide 17: Q & A
Q & A Biomea Fusion 900 Middlefield Road, 4th floor Redwood City, CA, 94063 biomeafusion.com Confidential 17
Slide 18: Thank You
THANK YOU Biomea Fusion 900 Middlefield Road, 4th floor Redwood City, CA, 94063 biomeafusion.com Confidential 18